60 minutes
As we better understand the genetics of disease, we can increasingly treat the underlying disease mechanisms rather than the superficial disease etiology. Biomarker testing toward improved drug effectiveness in defined sub-groups have made this a reality. Unlike oncology, where this concept is now mainstream, how might precision medicine apply to large patient populations like cardiovascular and neurodegenerative diseases? This panel will discuss the challenges and opportunities for precision medicine in these widespread maladies.


Barbara Tate - Chief Strategy Officer, Dementia Discovery Fund
Calum MacRae - Vice Chair, Scientific Innovation Associate Professor, Harvard Medical School
Shawn Murphy - Chief Research Information Officer, Partners HealthCare
Name Audience
Science Track